For more information on VWD visit the Project Red Flag web site at http://www.projectredflag.org or call the National Hemophilia Foundation's Information Resource Center at 1-800-42-HANDI (email to email@example.com). Trained staff members are available Monday through Friday, 9 a.m. to 5:00 p.m. EST to answer your requests.
About the National Hemophilia Foundation and Project Red Flag
The National Hemophilia Foundation is dedicated to finding better treatments and cures for bleeding and clotting disorders and to preventing the complications of these disorders through education, advocacy and research.
Established in 1948, the National Hemophilia Foundation is a non profit 501(c)3 organization with chapters throughout the country. Its programs and initiatives are made possible through the generosity of individuals, corporations and foundations as well as through a cooperative agreement with the Centers for Disease Control and Prevention (CDC).
For more information about the National Hemophilia Foundation visit http://www.hemophilia.org.
About CSL Behring
CSL Behring is a global leader in the plasma protein biotherapeutics
industry. Passionate about improving the quality of patients' lives, CSL
Behring manufactures and markets a range of safe and effective
plasma-derived and recombinant products and related services. The company's
therapies are used in the treatment of immune deficiency disorders,
hemophilia, von Willebrand disease, other bleeding disorders and inherited
emphysema. Products include Humate P(R) Antihemophilic Factor/von
Willebrand Factor Complex (Human) Dried, Pasteurized, for the treatment of
von Willebrand Disease, and Helixate(R) FS a recombinant factor VIII
|SOURCE National Hemophilia Foundation|
Copyright©2008 PR Newswire.
All rights reserved